New biopsy test could predict chemo success in breast cancer

NCT ID NCT03524430

Ongoing Knowledge-focused Sponsor: Rna Diagnostics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new lab test called the RNA Disruption Assay (RDA) to see if it can tell how well breast cancer is responding to chemotherapy. Researchers will take small tissue samples (biopsies) from the tumor at specific times during treatment and analyze them. The goal is to see if the test results match up with whether the tumor completely disappears after treatment. About 800 women with early-stage breast cancer are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could give doctors a way to tell early on whether chemotherapy is working for a breast cancer patient, allowing them to switch treatments sooner if needed.
What could go wrong: This is an observational study, not a treatment trial. The test is still being validated and may not reliably predict outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM FEMALE

Contacts and locations

Locations

Hospital U. 12 de Octubre

Madrid, Spain
Institut de Cancerologie de Strasbourg

Strasbourg, France
NZOZ Neuromed

Lublin, Poland
SST di Cremona Multidisciplinare di Patologia Mammaria, Italy

Cremona, Italy
Siteman Cancer Center

St Louis, Missouri, 63129, United States
Sunnybrook Health Sciences Center

Toronto, Canada
Universitätsklinikum Münster

Münster, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.